PASA (Predictor of Subclinical Atherosclerosis)

This 600-patient study will further examine the relationship between skin tissue cholesterol (sterol) and carotid intima media thickness (CIMT), which is an established predictor of heart attack and stroke.   The study is expected to provide data to support broader regulatory clearance for PREVU* Point of Care (POC) Skin Sterol Test as a tool to identify asymptomatic patients at risk of a primary event, such as heart attack. 

The study will include 600 asymptomatic patients between 40 to 80 years of age with low (<10%), intermediate (10% - 20%) and high (>20%) 10-year Framingham Global Risk scores.   Patients will be evaluated using PREVU* POC, PREVU* LT, blood testing and CIMT.   PASA will be conducted at several sites in the United States, led by the University of Wisconsin and including University of Chicago, University of Pennsylvania Health System, Johns Hopkins University and Radiant Research - Chicago.

View Abstract - Usefulness of Increased Skin Cholesterol to Identify Individuals at
Increased Cardiovascular Risk (from the Predictor of Advanced
Subclinical Atherosclerosis Study)